Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews · Epilepsy

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 33.3%Low 1 · 33.3%Moderate 0 · 0%High 1 · 33.3%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Topiramate vs placebo · Adverse effects ‐ 'thinking abnormally'
  Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
  RR 5.7 [2.26, 14.38]
  4 studies · 640 participants
  High
Direct match · question page
- Vigabatrin vs placebo · Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks
  Vigabatrin add‐on therapy for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
  RR 1.64 [0.67, 4.02]
  5 studies · 430 participants
  Very low
Related · question page
- Abnormal vs normal EEG · Seizure relapse rate by EEG findings
  Early versus late antiepileptic drug withdrawal for people with epilepsy in remission 2015 · Cochrane Headline outcomes only
  RR 1.44 [1.13, 1.83]
  2 studies · 618 participants
  Low

Abnormal vs normal EEG

Seizure relapse rate by EEG findings · individuals with epilepsy in remission

Abnormal may leads to higher seizure relapse rate by EEG findings compared with normal EEG (low certainty).

1 finding from 1 review

Early versus late antiepileptic drug withdrawal for people with epilepsy in remission 2015 · Cochrane Headline outcomes only
RR 1.44 [1.13, 1.83]
2 studies · 618 participants
Low

Vigabatrin vs placebo

Adverse effects: abnormal vision Duration of treatment (range): 8–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy

It is very uncertain whether vigabatrin changes adverse effects: abnormal vision Duration of treatment (range): 8–36… compared with placebo (very low certainty).

1 finding from 1 review

Vigabatrin add‐on therapy for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only
RR 1.64 [0.67, 4.02]
5 studies · 430 participants
Very low

Topiramate vs placebo

Adverse effects ‐ 'thinking abnormally' · people with drug‐resistant focal epilepsy

Topiramate leads to higher adverse effects ‐ 'thinking abnormally' compared with placebo (high certainty).

1 finding from 1 review

Topiramate add‐on therapy for drug‐resistant focal epilepsy 2019 · Cochrane Headline outcomes only
RR 5.7 [2.26, 14.38]
4 studies · 640 participants
High